POGO® Automatic Blood Glucose Monitoring System Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Walnut Creek, California, United States, 94598
- Diablo Clinical Reasearch
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55416
- Park Nicollett Institute - International Diabetes Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Be diagnosed with diabetes
- Be 18 years of age or older
- Be able to read, write, and understand English fluently
- Be able and willing to give written informed consent and have provided signed, written consent
Exclusion Criteria:
- Any condition which in the opinion of the Investigator may place the subject or site personnel at excessive risk
- A physical condition or limitation that prevents the subject from reading the labeling and using a BGMS on their own
- Previous experience with the POGO® BGMS
- Formal experience with clinical (medical) laboratory equipment or formal training in a relevant medical field
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PWD testing POGO® BGMS
All enrolled persons with diabetes
|
SMBG
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy Validation of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.
Time Frame: Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.)
|
Lay-user accuracy
|
Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.)
|
|
Accuracy Verification of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.
Time Frame: Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.)
|
HCP accuracy
|
Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TP-000321
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.